Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers.

Nevler A, Muller AJ, Sutanto-Ward E, DuHadaway JB, Nagatomo K, Londin E, O'Hayer K, Cozzitorto JA, Lavu H, Yeo TP, Curtis M, Villatoro T, Leiby BE, Mandik-Nayak L, Winter JM, Yeo CJ, Prendergast GC, Brody JR.

Clin Cancer Res. 2019 Jan 15;25(2):724-734. doi: 10.1158/1078-0432.CCR-18-0814. Epub 2018 Sep 28.

PMID:
30266763
2.

A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2.

Nevler A, Muller AJ, Cozzitorto JA, Goetz A, Winter JM, Yeo TP, Lavu H, Yeo CJ, Prendergast GC, Brody JR.

J Am Coll Surg. 2018 Apr;226(4):596-603. doi: 10.1016/j.jamcollsurg.2017.12.052. Epub 2018 Feb 7.

3.

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors.

Chand SN, Zarei M, Schiewer MJ, Kamath AR, Romeo C, Lal S, Cozzitorto JA, Nevler A, Scolaro L, Londin E, Jiang W, Meisner-Kober N, Pishvaian MJ, Knudsen KE, Yeo CJ, Pascal JM, Winter JM, Brody JR.

Cancer Res. 2017 Sep 15;77(18):5011-5025. doi: 10.1158/0008-5472.CAN-16-2704. Epub 2017 Jul 7.

4.

Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.

Zarei M, Lal S, Parker SJ, Nevler A, Vaziri-Gohar A, Dukleska K, Mambelli-Lisboa NC, Moffat C, Blanco FF, Chand SN, Jimbo M, Cozzitorto JA, Jiang W, Yeo CJ, Londin ER, Seifert EL, Metallo CM, Brody JR, Winter JM.

Cancer Res. 2017 Aug 15;77(16):4460-4471. doi: 10.1158/0008-5472.CAN-17-0015. Epub 2017 Jun 26.

5.

Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: native ribonucleoprotein immunoprecipitation (RIP) assays.

Cozzitorto JA, Jimbo M, Chand S, Blanco F, Lal S, Gilbert M, Winter JM, Gorospe M, Brody JR.

Methods Mol Biol. 2015;1262:239-46. doi: 10.1007/978-1-4939-2253-6_14.

PMID:
25555585
6.

MUC1 Promoter-Driven DTA as a Targeted Therapeutic Strategy against Pancreatic Cancer.

Tholey RM, Lal S, Jimbo M, Burkhart RA, Blanco FF, Cozzitorto JA, Eisenberg JD, Jiang W, Iacobuzio-Donahue CA, Witkiewicz AK, Glbert M, Yeo CJ, Brody JR, Sawicki JA, Winter JM.

Mol Cancer Res. 2015 Mar;13(3):439-48. doi: 10.1158/1541-7786.MCR-14-0199. Epub 2014 Oct 21.

7.

HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.

Lal S, Burkhart RA, Beeharry N, Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris ZA, Yeo CJ, Sawicki JA, Winter JM, Rigoutsos I, Yen TJ, Brody JR.

Cancer Res. 2014 Feb 15;74(4):1128-40. doi: 10.1158/0008-5472.CAN-13-1915.

8.

HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.

Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, Winter JM.

RNA Biol. 2013 Aug;10(8):1312-23. doi: 10.4161/rna.25274. Epub 2013 Jun 13.

9.

Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.

Burkhart RA, Peng Y, Norris ZA, Tholey RM, Talbott VA, Liang Q, Ai Y, Miller K, Lal S, Cozzitorto JA, Witkiewicz AK, Yeo CJ, Gehrmann M, Napper A, Winter JM, Sawicki JA, Zhuang Z, Brody JR.

Mol Cancer Res. 2013 Aug;11(8):901-11. doi: 10.1158/1541-7786.MCR-12-0699. Epub 2013 May 21.

10.

HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.

Pineda DM, Rittenhouse DW, Valley CC, Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin ER, Rigoutsos I, Yeo CJ, Gorospe M, Witkiewicz AK, Sachs JN, Brody JR.

Cancer Biol Ther. 2012 Aug;13(10):946-55. doi: 10.4161/cbt.20952. Epub 2012 Aug 1.

11.

pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.

Williams TK, Costantino CL, Bildzukewicz NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen JC, Dasgupta A, Gorospe M, Gonye GE, Yeo CJ, Witkiewicz AK, Brody JR.

PLoS One. 2010 Nov 29;5(11):e15455. doi: 10.1371/journal.pone.0015455.

12.

CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapy.

Huang YH, Cozzitorto JA, Richards NG, Eltoukhy AA, Yeo CJ, Langer R, Anderson DG, Brody JR, Sawicki JA.

Cancer Biol Ther. 2010 Nov 1;10(9):878-84. doi: 10.4161/cbt.10.9.13234. Epub 2010 Nov 1.

13.

HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.

Richards NG, Rittenhouse DW, Freydin B, Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody JR, Witkiewicz AK.

Ann Surg. 2010 Sep;252(3):499-505; discussion 505-6. doi: 10.1097/SLA.0b013e3181f1fd44.

PMID:
20739850
14.

The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

Costantino CL, Witkiewicz AK, Kuwano Y, Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M, Brody JR.

Cancer Res. 2009 Jun 1;69(11):4567-72. doi: 10.1158/0008-5472.CAN-09-0371.

Supplemental Content

Loading ...
Support Center